H.R. 4376 · 117th Congress · House

USTRx Act

Active· Referred to the Subcommittee on Trade.
Introduced
Jul 9, 21
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Use Sovereignty To reduce Rx Act or the USTRx Act

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative (USTR) to conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

Action Timeline

4
  1. JUL 09, 2021IntroReferral

    Introduced in House

  2. JUL 09, 2021IntroReferral

    Introduced in House

  3. JUL 09, 2021IntroReferral

    Referred to the House Committee on Ways and Means.

  4. JUL 09, 2021Committee

    Referred to the Subcommittee on Trade.

Committees

2

Trade Subcommittee

hswm04

Referred: Jul 9, 2021

Active

Ways and Means Committee

hswm00

Referred: Jul 9, 2021

Active